Fig. 1.

(a) Treatment with dendritic cell (DC)/tumour-fusion vaccine alone. In one course, DC/tumour-fusion vaccine was injected subcutaneously every 2 weeks, for a total of six times in 12 weeks. (b) Treatment with DC/tumour-fusion vaccine plus recombinant human interleukin (rhIL)-12. In the first week, DC/tumour-fusion vaccine was injected subcutaneously on day 1, and rhIL-12 on days 3 and 6 on the same place of the patients’ skin. The second week was a drug holiday. One cycle consisted of these 2 weeks. One course consisted of three cycles.